Sehn, L. H. Et Al. 2020. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.2 , 155-176.

Sehn, L. H., Herrera, A. F., Flowers, C. R., Kamdar, M. K., McMillan, A., Hertzberg, M., ... Assouline, S.(2020). Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.2, 155-176.

Sehn, Laurie Et Al. "Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma," JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.2, 155-176, 2020

Sehn, Laurie H. Et Al. "Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma." JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.2, pp.155-176, 2020

Sehn, L. H. Et Al. (2020) . "Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma." JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.2, pp.155-176.

@article{article, author={Laurie H. Sehn Et Al. }, title={Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2020, pages={155-176} }